Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 21, 2008. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs), specifically detailing the vesting of share awards and the exercisability of share options granted in 2004 under the company's Performance Share Plan (PSP) and Share Option Plan (SOP).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation outcomes rather than operational financial performance.
Material Changes and Compensation Outcomes
The filing details the conclusion of the three-year performance period (January 1, 2005, to December 31, 2007) for awards made in 2004.
- Performance Share Plan (PSP): Vesting was determined based on relative Total Shareholder Return (TSR) for Executive Directors and CET members, and a combination of TSR and Earnings per Share (EPS) growth for other participants. Unvested balances lapsed.
- Share Option Plan (SOP): Performance conditions were met, confirming that awards made to appointed CET members are exercisable in full. The option price was GBP11.23 (or US$43.730 for ADSs).
Specific vesting and exercise allocations for key executives include:
| Executive | PSP Shares/ADSs Vested | SOP Shares/ADSs Exercisable |
|---|---|---|
| Dr. JP Garnier (Executive Director) | 86,327 | 460,000 |
| Mr. A P Witty (Executive Director) | 33,272 | 177,500 |
| Mr. R M Bondy | 33,272 | 177,500 |
| Mr. D M Stout | 31,941 | 170,000 |
| Mr. J M Clarke | 20,687 | N/A |
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on future strategy, or specific risk factors. The document is a regulatory notification of past compensation events.
Key Facts for Investor Verification
- Verify the impact of the 2004 PSP vesting on the company's share count and dilution, noting that unvested balances lapsed.
- Confirm the exercise status of the SOP awards, which were confirmed exercisable in full following the meeting of performance conditions.
- Review the specific performance metrics (TSR and EPS growth) used to determine the vesting percentages for the 2004 awards.
- Note that Dr. R G Greig's PSP award is deferred until retirement.